(Q38049628)

27 August 2017

title

Disease-specific therapy of idiopathic inflammatory demyelinating disorders (English)

1 reference

27 August 2017

Mohsen Khoshnam

1

1 reference

27 August 2017

Mark S Freedman

series ordinal

2

1 reference

27 August 2017

publication date

1 September 2012

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

27 August 2017

published in

1 reference

27 August 2017

volume

12

1 reference

27 August 2017

issue

9

1 reference

27 August 2017

page(s)

1113-1124

1 reference

The pathological spectrum of CNS inflammatory demyelinating diseases

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Homogeneity of active demyelinating lesions in established multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

New imaging techniques in the diagnosis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Relationship between systemic corticosteroids and osteonecrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

High-Dose Corticosteroid Treatment Is Associated with an Increased Risk of Developing Cerebral Venous Thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Primary central nervous system lymphoma in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Melanoma complicating treatment with natalizumab for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Fingolimod-associated macular edema: incidence, detection, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

The origins of concentric demyelination: self-organization in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Astrocytopathy in Balo's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Images in clinical medicine. Baló's concentric sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Aquaporin-4 astrocytopathy in Baló’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

A second case of Marburg's variant of multiple sclerosis with vasculitis and extensive demyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

High dose cyclophosphamide treatment in Marburg variant multiple sclerosis A case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Natural history of multiple sclerosis with childhood onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Consensus definitions proposed for pediatric multiple sclerosis and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Acute disseminated encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Severe steroid-resistant post-infectious encephalomyelitis: general features and effects of IVIg

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Neuromyelitis optica in France: a multicenter study of 125 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Revised diagnostic criteria for neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

A case of paraneoplastic myelopathy associated with the neuromyelitis optica antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

A possible paraneoplastic neuromyelitis optica associated with lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

EFNS guidelines on diagnosis and management of neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Presentation, management and follow-up of Schilder's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Monoclonal antibody treatments for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Interferon-beta mechanisms of action in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

The mechanism of action of glatiramer acetate treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Adult Type of Neuronal Ceroid Lipofuscinosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

Safety and efficacy of natalizumab in children with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.101

21 January 2018

Identifiers

DOI

10.1586/ERN.12.101

1 reference

27 August 2017

1 reference